


Have a seat and enjoy.



Fresenius Renal Pharma **Breakfast Symposium**

„Magnesium – beneficial effects over & above phosphate binding“

🎵 May 13, 2011 🎵 7.45 – 8.45 am 🎵 Auditorium 1 🎵 Special breakfast served

The Nordic Kidney Days | May 12 – 14, 2011

Tivoli Congress Center | Arni Magnussonsgade 2-4 | DK-1577 Copenhagen V | Booth no. 21

OsvaRen® 435 mg/235 mg film-coated tablets. Composition: Each film-coated tablet contains: Calcium acetate, 435.00 mg equivalent to 110 mg calcium and magnesium carbonate, heavy 235.00 mg equivalent to 60 mg magnesium. **Excipients:** Tablet core: Starch, pregelatinised, from maize, maize starch, sucrose, gelatine, croscarmellose sodium, magnesium stearate. Film coating: Castor oil, refined, hypromellose. **Indications:** Treatment of hyperphosphataemia associated with chronic renal insufficiency in patients undergoing dialysis (haemodialysis, peritoneal dialysis). **Contraindications:** OsvaRen® is contraindicated in patients with Hypophosphataemia, Hypercalcaemia with or without clinical symptoms, e.g. as a result of an overdose of vitamin D, a paraneoplastic syndrome (bronchial carcinoma, breast cancer, renal cell carcinoma, plasmacytoma), bone metastases, sarcoidosis or immobilisation osteoporosis; Elevated serum magnesium levels of more than 2 mmol/l, and/or symptoms of hypermagnesaemia; AV-block III°; Myasthenia gravis; Hypersensitivity to the active substances or to any of the excipients. **Side effects:** Very common (≥1/10), common (≥ 1/100 and <1/10), uncommon (≥1/1,000 and <1/100), rare (≥1/10,000 and <1/1,000), very rare (<1/10,000), not known (cannot be estimated from the available data). Gastrointestinal disorders: Common: Soft stools, gastrointestinal irritation like nausea, anorexia, sensation of fullness, belching and constipation, diarrhoea. Metabolism and nutrition disorders: Common: Hypercalcaemia either asymptomatic or symptomatic, asymptomatic hypermagnesaemia. Uncommon: Moderate to severe symptomatic hypercalcaemia, symptomatic hypermagnesaemia. Very rare: Hyperkalaemia, magnesium-induced osteal mineralisation disturbances. **Special warning:** Contains sodium (not more than 5.6 mg per each film coated tablet) and sucrose. Read the package leaflet before use. **Supply classification:** Prescription only medicine. **Fresenius Medical Care Nephrologica Deutschland GmbH.** 61346 Bad Homburg v.d.H., Germany. **Date:** February 2010. **The names of this medicinal product in the Member States of the EEA are as follows:** B: Renepho, Other countries: OsvaRen® OsvaRen® has received marketing authorisations in: A, B, CY, CZ, D, DK, E, EST, F, FIN, GB, GR, H, IRL, IS, IT, L, LT, LV, M, N, NL, P, PL, S, SK, SLO, SRB (status: February 2010). The registration procedure for other countries is currently in progress.

